$960.04
-21.29-2.17%
In chiusura: Nov 13, 4:00 PM EST
$960.04
N/A
Post-mercato: 4:00 PM EST
argenx rose 7.7% from $891.73 to $960.04, behind the S&P 500's +12.3%. Its worst day was Oct 8 (−11.8%), and its low came Mar 20 at $663.93.
Nov 13, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $8.02 beat the $5.64 estimate on $1.3B revenue (est. $1.2B).
−5.6% · S&P 500 −0.6%
argenx closed at its lowest level of the year, 25.5% below where the year started.
Story events cover the past 12 months · Times ET
−3.0% · S&P 500 −1.4%
EPS of $5.52 beat the $4.39 estimate on $1.3B revenue (est. $1.2B).
−2.5% · S&P 500 −0.3%
EPS of $7.32 beat the $5.56 estimate on $1.5B revenue (est. $1.3B).
+8.6% · S&P 500 −1.2%
Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)Patient improvements observed early and sustained throughout study;
+16.0%, the year's best day · S&P 500 −0.5%
argenx closed at its highest level of the year, 18.7% above where the year started.
+1.1% · S&P 500 +0.7%
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac diseaseargenx plans
−11.8%, the year's worst day, on 2M shares, the year's heaviest volume · S&P 500 −0.4%
EPS of $7.80 beat the $-20.78 estimate on $1.8B revenue (est. $1.6B).
−1.6% · S&P 500 −1.2%
Where it ended: a close of $960.04 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $7.37, revenue est. $1.9B).
Nothing in the past 12 months.
All ARGX dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ARGX and SPY from Benzinga historical bars. Not investment advice.